Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.

Paweł Rajwa Shahrokh F ShariatIsabel HeideggerFabio ZattoniGiancarlo MarraTimo F W SoeterikRoderick C N van den BerghMassimo ValerioFrancesco Ceci Claudia V Kesch Veeru Kasivisvanathan Ekaterina Laukhtina Tatsushi KawadaPeter NyiriadiQuoc-Dien TrinhPiotr ChlostaPierre I KarakiewiczGuillaume PloussardAlberto BrigantiFrancesco MontorsiShahrokh F ShariatGiorgio Gandaglianull null

Published in: Prostate cancer and prostatic diseases (2022)

Patients with mHSPC benefit from combination systemic therapies irrespective of age; the effect is, however, more evident in younger patients. Chronological age alone seems not to be a selection criteria for the administration of combination systemic therapies.

Keyphrases

prostate cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
radical prostatectomy
peritoneal dialysis
patient reported outcomes